Division of Gynecologic Oncology

Medicine & Life Sciences

1. Endometrial Neoplasms 100%
2. Ovarian Neoplasms 70%
3. Neoplasms 60%
4. Uterine Cervical Neoplasms 57%
5. HIV 33%
6. Survival 33%
7. Colposcopy 30%
8. Carcinoma 29%
9. Cell Biology 21%
10. Ovarian Epithelial Carcinoma 20%
11. Cervical Intraepithelial Neoplasia 20%
12. Drug Therapy 19%
13. Therapeutics 18%
14. Platinum 18%
15. Papanicolaou Test 17%
16. Paclitaxel 17%
17. Mutation 17%
18. Microsatellite Instability 17%
19. Carcinosarcoma 16%
20. Radiotherapy 15%
21. Squamous Intraepithelial Lesions 15%
22. Recurrence 14%
23. Neoplasm Metastasis 13%
24. Hysterectomy 13%
25. Early Detection of Cancer 13%
26. Lymph Nodes 12%
27. Carboplatin 12%
28. Progression-Free Survival 12%
29. Bevacizumab 12%
30. DNA Mismatch Repair 12%
31. Uterine Neoplasms 11%
32. Cisplatin 11%
33. Cervix Uteri 11%
34. Guidelines 11%
35. Confidence Intervals 10%
36. Fallopian Tubes 10%
37. Radiation 10%
38. Biopsy 10%
39. Methylation 9%
40. Hereditary Nonpolyposis Colorectal Neoplasms 9%
41. Vulvar Neoplasms 9%
42. Atypical Squamous Cells of the Cervix 9%
43. Positron-Emission Tomography 9%
44. Cell Line 9%
45. Brachytherapy 8%
46. Oncologists 8%
47. Papillomavirus Infections 8%
48. Histology 8%
49. Vulva 7%
50. Pathology 7%
51. Endometrioid Carcinoma 7%
52. Incidence 7%
53. Topotecan 7%
54. Genes 6%
55. Ovary 6%
56. gemcitabine 6%
57. Adenocarcinoma 6%
58. Uterine Cervical Dysplasia 6%
59. Sarcoma 6%
60. Gynecology 5%
61. Human papillomavirus 16 5%
62. Gestational Trophoblastic Disease 5%
63. liposomal doxorubicin 5%
64. Uterus 5%